Recommendation We upgrade our recommendation to a Strong BUY, as AVX’s major competitor in the HIV market – Incyte – had its Reverset product knocked back from Phase III trials by the US FDA.
AVX Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
